SMA is a rare disease and is on of the leading genetic causes of infant death. Affecting one in every 11,000 babies born., and if left untreated, it is one of its most severe forms, 90% of children require permanent feeding and breathing support or pass away by their second birthday.
Dr. Sandy Reyna, the Vice President of Global Medical Affairs at Novartis Gene Therapies, and Kathryn McBride, SMA parent advocate share information on the signs of SMA, the importance of newborn screening and an early diagnosis, and how Zolgensma has the potential to transform the lives of babies born with the devastating genetic disease.
For more information visit: www.Zolgensma.com
